The Resource Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)

Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)

Label
Development of PRO-140 (Leronlimab) as a treatment for COVID-19
Title
Development of PRO-140 (Leronlimab) as a treatment for COVID-19
Statement of responsibility
Jacob Lalezari
Creator
Speaker
Subject
Language
eng
Member of
Accompanying matter
technical information on music
Cataloging source
UkLoHST
http://library.link/vocab/creatorName
Lalezari, Jacob,
Series statement
Research and clinical interviews,
http://library.link/vocab/subjectName
  • Coronavirus infections
  • COVID-19 (Disease)
  • Drug development
  • CCR5 Receptor Antagonists
  • Coronavirus Infections
  • COVID-19
  • Drug Development
  • Inflammation
  • leronlimab
  • Pharmaceutical Preparations
  • Receptors, CCR5
  • severe acute respiratory syndrome coronavirus 2
Label
Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)
Instantiates
Publication
Note
  • Audio interview
  • Title from title frames
Color
not applicable
Configuration of playback channels
monaural
Contents
Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?
Control code
HST8159
Dimensions
  • unknown
  • not applicable
Extent
1 online resource (1 streaming audio file (20 min.)).
Form of item
online
Groove width / pitch
not applicable
Kind of cutting
not applicable
Kind of disc cylinder or tape
not applicable
Kind of material
other
Publisher number
8159
Sound
sound
Special playback characteristics
digital recording
Specific material designation
remote
System control number
(UkLoHST)4246
Tape configuration
not applicable
Tape width
not applicable
Label
Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)
Publication
Note
  • Audio interview
  • Title from title frames
Color
not applicable
Configuration of playback channels
monaural
Contents
Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?
Control code
HST8159
Dimensions
  • unknown
  • not applicable
Extent
1 online resource (1 streaming audio file (20 min.)).
Form of item
online
Groove width / pitch
not applicable
Kind of cutting
not applicable
Kind of disc cylinder or tape
not applicable
Kind of material
other
Publisher number
8159
Sound
sound
Special playback characteristics
digital recording
Specific material designation
remote
System control number
(UkLoHST)4246
Tape configuration
not applicable
Tape width
not applicable

Library Locations

Processing Feedback ...